NCT02879760已完成1 期
A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 12
- 主要终点
- Phase 1 - Toxicity as measured by adverse events
研究概览
简要总结
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at least 1 cycle of platinum based chemotherapy and/or at least one treatment of PD-1 or PD-L1 antibody targeted therapy.
详细描述
This is a Phase 1/2, open-label, dose-escalation trial of Ad MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with NSCLC (histological subtype of squamous and non-squamous NSCLC). In Phase 1, patients who have progressed after treatment with a platinum-based regimen and/or PD-1/PD-L1 targeted antibody therapy will be enrolled. In Phase 2, only patients who have progressed after treatment regimen containing PD-1/PD-L1 targeted antibody therapy will be enrolled. In the Phase 1 portion of the study, MG1-MAGEA3 treatment will be escalated in a sequential dose-escalating design. In the Phase 2 portion of the study, MG1-MAGEA3 treatment will be at the maximum tolerated dose (MTD) or the maximum feasible dose (MFD). The Ad-MAGEA3 and pembrolizumab dose is fixed in both the Phase 1 and Phase 2 portions of the trial.
Phase 1 Enrollment
Cohorts 1 through 5:
Three patients will be treated at each dose level unless a dose-limiting toxicity (DLT), as defined below, is observed. Patients will be observed for a DLT through Day 29. After enrollment of the first patient in each cohort, 2 additional patients will be enrolled after the initial patient reaches Day 29 without experiencing a DLT. Treatment with MG1-MAGEA3 will proceed to the next dose level if 0 of 3 patients experiences a DLT. If one of the first 3 patients experiences a DLT, additional patients will be enrolled until a second patient experiences a DLT (which defines the toxic dose) or until 6 total patients have been treated, whichever comes first. If a second DLT is not experienced within that cohort, dose escalation may continue.
If 2 DLTs are observed within a cohort, enrollment into the cohort will cease and the dose level immediately preceding that dose will be determined as the MTD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In order to be eligible for participation in this trial, the patient must:
- •Have histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) with positive expression of MAGE-A3 (primary or metastatic lesion).
- •Phase 1: Have radiographic progression after treatment with at least 1 cycle of platinum-doublet chemotherapy and/or at least one treatment of PD-1 or PD-L1 antibody targeted therapy. Adjuvant therapy will count as a regimen if administered within 1 year before relapse.
- •Phase 2: Have radiographic progression during or after treatment with anti-PD-1/PD-L1 antibody. Adjuvant therapy will count as regimen if administered within 1 year before relapse.
- •Phase 1: Patients with tumors of non-squamous NSCLC histology that have a known epidermal growth factor receptor (EGFR) mutation and/or anaplastic lymphoma kinase (ALK) translocation can participate in the Phase 1 portion of the study if they have failed the appropriate tyrosine kinase inhibitor (TKI) (intolerance or documented progression of their NSCLC) and have documented progression of their NSCLC. There is no preferred order of treatment with TKI or platinum doublet therapy. If a patient is found to have one molecular alteration (either sensitizing EGFR mutation or ALK translocation), then testing for the other alteration is not required.
- •Phase 2: Patients with the above ALK and EGFR targetable mutations will not be eligible for treatment.
- •Have measurable disease based on RECIST v1.1 criteria as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions post irradiation treatment.
- •Have at least one tumor amenable to biopsy.
- •Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Demonstrate adequate organ function:
- •White blood cell (WBC) count ≥3,000 cells/mm3
- •Absolute neutrophil count (ANC) ≥1,000 cells/mm3
- •Hemoglobin ≥8 g/dL or ≥4.96 mmol/L (correction with transfusion or erythropoietin-based therapy allowed to meet eligibility criteria)
- •Platelet count ≥100,000 platelets/mm3 (untransfused)
- •Total bilirubin ≤1.5 x Upper Limit of Normal (ULN) OR direct bilirubin ≤ULN for patients with total bilirubin levels >1.5 x ULN (i.e., patients with Gilberts disease)
- •Aspartate transaminase (AST), alanine aminotransferase (ALT) ≤2.5 x ULN; ≤5.0 x ULN if patient has liver metastases
- •Serum chemistries Sodium, Potassium, and Calcium within normal limits (WNL) or Grade 1
- •Serum creatinine ≤1.5 x ULN or creatinine clearance ≥60 mL/min for patient with creatinine levels >1.5 institutional ULN according to Cockcroft-Gault formula
- •Serum phosphate >0.8 mmol/L (Grade 0-1)
- •International normalized ratio (INR) ≤1.5 x ULN unless patient is receiving anticoagulant therapy as long as prothrombin time (PT) or partial prothrombin time (PTT) is within therapeutic range of intended use of anticoagulants
- •Activated partial thromboplastin time (aPTT) ≤1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- •Resting oxygen saturation on room air ≥ 90%
- •Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Female patients of childbearing potential (refer to Section 11.A.2.c) must be willing to use an adequate method of contraception as outlined in Section 11.A.2.c, starting with Day 1 through 120 days after the last dose of study medication.
- •Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
- •Male patients of reproductive potential (Section 11.A.2.c) must agree to use an adequate method of contraception as outlined in Section 11.A.2.c, starting with Day 1 through 120 days after the last dose of study medication.
- •Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.
- •Be willing and able to provide written informed consent for the trial.
- •Be 18 years of age (or legal age of majority in the jurisdiction) on day of signing informed consent.
排除标准
- •The patient must be excluded from participating in the trial if the patient:
- •Has disease that is suitable for local therapy administered with curative intent.
- •Has had prior treatment with any MAGE-A3 vaccine immunotherapy including Ad-MAGEA3 or MG1-MAGEA
- •Is currently receiving experimental therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •Has had prior anti-cancer monoclonal antibody (mAb) therapy within 4 weeks prior to study Day 1 or failure to recover (i.e., to ≤ Grade 1 or to baseline status) from adverse events (AEs) due to agents administered more than 4 weeks earlier.
- •Has been intolerant of prior PD-1/PD-L1 targeted antibody therapy for which re-treatment would expose the patient to clinically significant risk in the opinion of the investigator (please attain sponsor permission of enrollment of any patient with prior intolerance to anti-PD-1/PD-L1 antibody treatment).
- •Has had prior chemotherapy, or targeted small molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or who has not recovered (i.e., to ≤ Grade 1 or to baseline status) from AEs due to a previously administered agent.
- •Note: Patients with ≤Grade 2 neuropathy or having any alopecia are an exception to this criterion and may qualify for the study.
- •Note: If patient received major surgery, they must be at least 4 weeks from surgery AND have recovered adequately from the toxicity and/or complications from the surgery prior to starting therapy.
- •Note: Patients receiving prior radiation must have recovered (< Grade 1) from any acute toxicity. Patients having irreversible but not clinically significant toxicity are eligible.
- •Note: Patients receiving prior lung radiation with a dose of >30 Gy must wait at least 8 weeks from the date of completion of the lung radiation before the first dose of pembrolizumab.
- •Has received prior treatment with vesicular stomatitis virus (VSV) based viral vector.
- •Requires use of anti-platelet or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies as per standard of care.
- •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Note: Patients with previously treated brain metastases who are stable may participate. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- •Has clinically significant tumor invasion (e.g., impeding obstruction) of a major vascular structure (e.g., carotid artery) or other key anatomical structure (e.g., pulmonary airway) or clinically significant and/or rapidly accumulating ascites, pericardial or pleural effusions.
- •Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Has evidence of active, non-infectious pneumonitis or current radiographic evidence of pneumonitis.
- •Has a history of interstitial lung disease.
- •Has an active infection requiring systemic therapy.
- •Has known active Hepatitis B (e.g., Hepatitis B surface antigen [HBsAg] reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) virus infection.
- •Has used anti-viral medication, within 14 days of enrollment.
- •Has conditions likely to have resulted in splenic dysfunction (e.g., splenectomy, sickle cell anemia, radiation to the spleen >20 Gy, congenital asplenism).
- •Has significant immunodeficiency due to underlying illness (e.g., known HIV/AIDS).
- •Has received immunosuppressive medication (e.g., systemic corticosteroids) within 4 weeks prior to the first dose of trial treatment.
- •Note: Patients must not be receiving doses of >10 mg/day of prednisone or equivalent at the time of study entry and corticosteroids may not be used for premedication.
- •Previous solid organ or allogeneic stem cell transplant.
- •Has uncontrolled pre-existing cardiovascular conditions and/or symptomatic cardiac dysfunction.
- •Has >Grade 2 dyspnea and/or requirement for supplemental oxygen.
- •Has received a live vaccine within 30 days of planned start of study therapy (Note: killed flu vaccine acceptable).
- •Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with Day 1 through 120 days after the last dose of study medication (including pembrolizumab).
- •History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins.
- •Patients with household contacts meeting any of the following criteria for study entry unless alternate living arrangements can be made, while under contact precautions (from the time of initial treatment with MG1-MAGEA3 until at least 7 days after the last dose of MG1-MAGEA3):
- •Women who are pregnant or nursing an infant
- •Children <1 year old; or
- •Individuals who are severely immunocompromised (including but not limited to: bone-marrow or organ transplant recipients; individuals with human Immunodeficiency virus [HIV] infection; individuals receiving chronic immunosuppressive medication such as systemic corticosteroids).
- •Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific patient.
结局指标
主要结局
Phase 1 - Toxicity as measured by adverse events
时间窗: 7 months
To determine the maximum tolerated dose MTD/ maximum feasible dose MFD of Ad/MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab
Phase 2 - Objective tumour response rate (ORR) based on RECIST v1.1
时间窗: 7 months
To evaluate objective tumour response rate (ORR) based on RECIST 1.1
次要结局
未报告次要终点
研究者
研究点 (12)
Loading locations...
相似试验
已完成
2 期
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT00385697MacroGenics554
撤回
1 期
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell CarcinomaMetastatic MelanomaSquamous Cell Skin CarcinomaNCT03773744Turnstone Biologics, Corp.
终止
1 期
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic MelanomaMalignant MelanomaNCT00145145Ludwig Institute for Cancer Research1
终止
1 期
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal CancerColorectal CancerNCT05497336Innovent Biologics (Suzhou) Co. Ltd.8
已完成
1 期
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationMultiple MyelomaNCT01380145Ludwig Institute for Cancer Research13